Sandoz Atorvastatina

Atorvastatina Sandoz is a prescription generic pharmaceutical product formulated to manage lipid levels and reduce cardiovascular disease risk.

Sandoz traces its roots back to Kern & Sandoz, established in Basel, Switzerland, in 1886. For many years, Sandoz operated as the generic and biosimilar pharmaceuticals division of the Swiss multinational healthcare company Novartis. In October 2023, Sandoz was successfully spun off from Novartis into an independent publicly traded company (Sandoz Group AG), headquartered in Basel, Switzerland.

Sandoz maintains active development and manufacturing operations across several European and international facilities (including manufacturing sites in Slovenia, Austria, and Spain), ensuring widespread distribution across pharmacy networks throughout Spain via Sandoz Farmacéutica, S.A.